With the recent string of regulatory reforms and NMPA joining ICH, China is poised to catch-up with the leading health authorities in bringing high-quality, low-cost, innovative medicines to its population and ensuring safe and effective use of medicinal products.
This white paper provides an overview of pharmacovigilance in China and recent regulatory reforms made to achieve standards on par with leading health authorities.
A closer examination is provided on the following topics: